Related Experiment Videos
Pancreas and islet cell transplantation
Rita Bottino1, Massimo Trucco, A N Balamurugan
1Division of Immunogenetics, Diabetes Institute, Department of Pediatrics, Children's Hospital of Pittsburgh, University of Pittsburgh, School of Medicine, Pittsburgh, PA 15213, USA.
Best Practice & Research. Clinical Gastroenterology
|June 25, 2002
Summary
Pancreas and islet cell transplantation can restore normal glucose control for type 1 diabetes patients. However, the immune response remains a significant barrier to widespread treatment.
Area of Science:
- Immunology
- Endocrinology
- Transplantation Science
Background:
- Type 1 diabetes management currently relies on exogenous insulin.
- Pancreas or islet cell transplantation offers definitive treatment by restoring beta-cell mass.
- Current transplantation methods are limited by donor shortage and the need for potent immunosuppression.
Purpose of the Study:
- To review the challenges and recent advances in pancreas and islet cell transplantation for type 1 diabetes.
- To highlight the critical role of the alloimmune response as a barrier to transplantation.
- To discuss the implications of recent mechanistic insights into alloengraftment for future therapeutic strategies.
Main Methods:
- Review of current literature on pancreas and islet cell transplantation.
- Analysis of the immunological challenges in transplantation.
- Discussion of recent advancements in understanding alloengraftment mechanisms.
Main Results:
- Transplantation can achieve long-term glucose homeostasis in type 1 diabetes.
- The alloimmune response is the primary obstacle to successful transplantation.
- Recent progress in understanding alloengraftment mechanisms is paving the way for improved outcomes.
Conclusions:
- Pancreas and islet cell transplantation are viable options for type 1 diabetes, but face significant immunological hurdles.
- Advances in understanding alloengraftment are crucial for overcoming the alloimmune response.
- Further research into immune tolerance is essential for broader application of beta-cell replacement therapies.